Eli Lilly Stock Rises 3.1% on Major Pipeline Data
Shares of Eli Lilly (LLY) climbed 3.1% in morning trading as the American Diabetes Association’s 86th Scientific Sessions opened in New Orleans, highlighting the company’s most significant pipeline results in years. The focus is on retatrutide, Lilly’s investigational triple-receptor agonist. In the Phase 3 TRIUMPH-1 trial, patients achieved an average weight loss of 70.3 lbs, or 28.3% of body weight over 80 weeks, outcomes comparable to bariatric surgery. Full trial data were presented publicly for the first time at the conference, giving investors renewed confidence in the drug’s potential to create a new category in obesity treatment.
Positive Results for Foundayo Enhance Momentum
Lilly also presented Phase 3 results for Foundayo, its oral GLP-1 pill, across three diabetes studies showing superiority over existing therapies. Adding to the bullish outlook, CVS Caremark confirmed formulary coverage for both Zepbound and Foundayo, meaning all three major U.S. pharmacy benefit managers now cover Lilly’s complete obesity drug portfolio. This milestone expands patient access and removes a key commercial barrier. Morgan Stanley reiterated an Overweight rating with a $1,344 price target, while TD Cowen raised its global GLP-1 market forecast to $150 billion by 2030.
Market Context and Competitor Comparison
The broader market contrasted sharply with Lilly’s strength, as the S&P 500 fell 1.0%, Nasdaq dropped 1.9%, and the Dow declined 0.3%, highlighting the company-specific nature of LLY’s move. While competitor Novo Nordisk is also presenting data at ADA 2026, Lilly’s retatrutide, described by William Blair analyst Andy Hsieh as a “different drug category” due to high potency, captured the bulk of investor attention.
Drivers Behind the Rally
The combination of a major clinical data catalyst, expanded insurance coverage, and continued bullish analyst sentiment has driven LLY to a new 52-week intraday high of $1,161.97, demonstrating that strong pipeline execution can outweigh broader market weakness, even in a risk-off trading session.
